Refractory, missed and severe Kawasaski disease: Diagnostic and therapeutic challenges by Comitis, George et al.
462
Refractory, missed and severe 
Kawasaski disease: Diagnostic and 
therapeutic challenges
have however reduced the acute mortality rate from about 2% in 
the 1970s to less than 0.2%.(2)
Prompt recognition of the disease and early initiation of treatment 
with intravenous polyvalent immunoglobulin (IVIG) (within the first 
10 days) results in significant reduction in the occurrence of 
CAA – from 15 - 25% to about 5%.(2) About half to 2 thirds of 
these will regress within the first 1 - 2 years (especially the smaller 
aneurysms) but others will persist with dilatation, stenoses, tor-
tuosity and thrombosis. In addition, despite IVIG, 1% still develop 
giant aneurysms (measuring 8mm or more). Furthermore, affected 
coronaries do not dilate normally with exercise or coronary vaso-
dilators (even if the lesions have regressed).(3,4) These persistent 
coronary lesions have obvious medium and long-term implications 
in adolescent and adult life, for example with regard to participa-
tion in sports and potential premature atherosclerotic coronary 
artery disease.(3) 
This article reports on a recent cluster of KD patients seen at 2 
hospitals in Cape Town. Each case highlights a particular learning 
point or challenge in the diagnosis or management.
CASE 1 – SEVERE KD
A 15-month-old previously well boy was admitted with diarrhoea 
and vomiting, cough and fever which had persisted for 4 days. On 
examination he was lethargic with a temperature of 38.6°C and an 
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Kawasaki disease (KD) is the most common acute vasculitis of 
childhood worldwide, affecting predominantly infants and young 
children with 80% of cases occurring below 5 years of age. It is 
currently the leading cause of acquired heart disease in children in 
the developed world.(1) 
The cause of KD remains unknown but is thought to be due to an 
abnormal immune response to an infectious trigger in a genetically 
predisposed individual.
Coronary artery abnormalities (CAA) are the main complication 
of KD and account for the majority of morbidity and mortality 
(mainly due to myocardial infarction secondary to acute thrombosis 
within coronary artery aneurysms). Current treatment regimens 
Kawasaki disease (KD) is an acute generalised vasculitis of 
childhood with a predilection for the coronary arteries 
causing ectasia and aneurysms with subsequent potential 
ischaemic heart disease and even sudden death. This risk is 
signifi cantly reduced by early treatment with intravenous 
immunoglobulin together with a high dose of aspirin. How-
ever, the diagnosis is often diffi cult to make as many childhood 
illnesses may mimic KD. In addition, presentations may be 
atypical or incomplete.
We discuss a series of 3 recent cases to focus on the manage-
ment of 3 potentially troublesome aspects of the disease 
namely: severe coronary vascular involvement, failure to 
recognise the disease and disease which is refractory to 
standard therapy. We will also provide a suggested treat- 
ment algorithm for refractory KD with reference to current 


















erythematous rash on the trunk. Initial investigations showed a 
white cell count (WCC) of 11.8 x 109/l with 58% bands, platelet 
count of 360 x 109/l and CRP 197mg/l.
The diagnosis of KD was made on day 2 - 3 of admission as his 
fever continued (up to 39.6°C), he was irritable and developed 
all 5 principal clinical features, viz. non-exudative conjunctivitis, 
erythematous rash on the trunk and face, oedema of the hands and 
feet, unilateral cervical lymphadenopathy and cracked lips with a 
red tongue.
At this stage (day 6 of fever) he received IVIG 2g/kg plus aspirin at 
moderate dose (40mg/kg/d). His temperature settled over the 
next 4 days but recurred on day 8 of admission /day 12 of illness 
(38.3°C).
An echocardiogram at this stage rather concerningly showed 
pancoronary dilatation as follows (Z scores(5) in brackets): left main 
coronary artery (LMCA) 4.3mm (+6.4), distal left anterior 
descending coronary artery (LAD) 5mm (+10.3), proximal cir-
cumflex coronary artery (Cx) 4mm (+7.0), right coronary artery 
(RCA) 3.5mm (+4.8).
Significantly there was a proximal LAD fusiform aneurysm of 
5.6mm and distal Cx saccular aneurysm of 6.1mm. Ventricular 
function was normal.
Based on these findings and the recurrence of fever, as well as 
rising inflammatory markers (WCC 22 x 109/l and CRP 322mg/l) he 
received a second dose of IVIG 2g/kg and his aspirin dose was 
increased to 90mg/kg/d. Thereafter his temperature settled and 
his clinical features steadily resolved. He also received pulsed 
steroids (methylprednisolone 30mg/kg/d) for 3 days during con-
valescence due to an isolated low grade fever of 37.7°C, a per-
sistently raised CRP of 57mg/l and ESR of 90mm/hr as well as 
painful arthritis of his ankles and knees with effusions.   
An echocardiogram on day 19 of illness showed an LAD fusiform 
giant aneurysm of 8 - 9mm with suspicion of intraluminal thrombus 
(Figure 1), distal Cx saccular aneurysm, dilated proximal RCA with 
a 5.5mm saccular aneurysm in mid-vessel and normal LV function. 
He was then started on low molecular weight heparin for 2 weeks 
and maintenance warfarin and his aspirin dose was reduced to 
3mg/kg/d. At 3 months an echocardiogram still showed aneurysms 
of the LAD, Cx and RCA. He remains asymptomatic.
Practice point
Cases of KD with this degree of coronary involvement (large aneu-
rysms of all 3 major coronaries) have rarely been reported in the 
literature.(6) The need for anti-coagulation of such (often young) 
patients (as prophylaxis against coronary thrombosis and myo-
cardial infarction) adds a further element of complexity to their 
management. Another important consideration in such patients is 
adequate and accurate coronary imaging – although transthoracic 
echocardiography remains the initial modality of choice, more 
definitive imaging with transoesophageal echocardiography, com-
puted tomographic angiography, magnetic resonance angiography 
or conventional coronary angiography is usually necessary to accu-
rately delineate the lesions, especially to assess if revascularisation 
is indicated. The present patient is awaiting conventional selective 
coronary angiography.
In addition, this case highlights the fact that severe CAA can still 
occur despite prompt, appropriate therapy with the current 
standard regimen of IVIG plus aspirin (see Figure 6). This example 
(and the following case) is in keeping with the fact that young 
infants with KD have the highest incidence of coronary artery 
aneurysms.
The recently published RAISE study(7) demonstrated reduced CAA 
in Japanese children with severe KD (defined using a validated risk 
score)(8) treated with adjuvant corticosteroids in addition to the 
standard regimen. However, the difficulty lies in identifying early 
which children are likely to be IVIG-resistant (and hence at a 
greater risk of developing CAA) in the South African context 
since these children would likely benefit from adjunctive corti-
costeroids. The Japanese scoring system has low sensitivity in 
North American populations(9) so may equally not be applicable 
in our setting.
FIGURE 1: Parasternal short axis view of LAD fusiform 
giant aneurysm in Case 1
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CASE 2 – MISSED KD
A 6-year-old boy was referred with a 1 week with a history of tiredness, loss of appetite, fast breathing and rapid heart pulsations. At 1 year 
of age he had a severe febrile illness associated with an erythematous rash and red lips which required admission and intravenous antibiotics 
for 1 week at another institution.
On examination, he appeared chronically ill with wasting. He was not shocked but his pulses were thready and he had obvious features of heart 
failure. He responded to conventional heart failure treatment with furosemide, spironolactone, captopril, carvedilol as well as low dose aspirin.
REFRACTORY, MISSED AND SEVERE KAWASASKI DISEASE
FIGURE 2: 12 lead ECG of Case 2 showing Q-waves in leads I, a VL and V5 with poor R-wave progression
FIGURE 3: Apical 4 chamber view in Case 2 showing a 
dilated left heart and echobright IVS and LV papillary 
muscles
FIGURE 4: Parasternal short axis view of proximal LAD 


















His ECG showed Q-waves in leads I, AVL and V5 with poor R-wave 
progression (Figure 2).
An echocardiogram revealed severely impaired LV systolic and 
diastolic function, and echobright LV papillary muscles and inter-
ventricular septum IVS suggesting infarcts in the LAD and RCA 
territories (Figure 3). There were obvious regional wall motion 
abnormalities with akinesia and poor thickening of the entire IVS 
and mid to apical posterior and lateral walls (only basal segments 
contracting normally). In addition there was a suspicion of an apical 
LV thrombus. His coronaries were dilated as follows (Z scores (5) 
in brackets): LMCA 4.6mm (+6.2), Cx 5.0mm (+8.6), distal LAD 
4.5mm (+7.8), distal RCA 2.5mm (+2.5).
Significantly, there was a proximal LAD fusiform aneurysm of 
7.7mm (Figure 4) as well as proximal RCA aneurysm of 5.5mm 
(Figure 5). As no other aetiology for his cardiomyopathy has been 
identified, the cause is presumed to be ischaemic in origin secondary 
to acquired CAA as above sustained during a missed episode of 
KD at 1 year of age.
Subsequent coronary angiography revealed a long segment occlu-
sion of the proximal LAD with some filling of the distal LAD via 
tiny collaterals. Further imaging is planned to detect viable myo-
cardium and reversible ischaemia (dobutamine stress echocar-
diogram and myocardial perfusion scan) to see if he will benefit 
from revascularisation.
Practice point
This case illustrates the significant morbidity that can accompany 
CAA secondary to KD and the potentially devastating effect of a 
missed diagnosis. Potentially many children with KD remain undiag-
nosed because of lack of awareness as well as a wide differential 
diagnosis such as viral infections (e.g. measles, adenovirus, entero-
virus, Epstein-Barr virus), scarlet fever, staphylococcal scalded skin 
and toxic shock syndromes and drug reactions including Stevens-
Johnson syndrome.
In addition 15% of children present with “incomplete” KD and 
CAA. These children do not fulfil the classic criteria but exhibit 
echocardiographic features of CAA. This is more common in 
young infants who are also at highest risk of CAA. Hence referral 
for echocardiography should be considered in all children with 
unexplained fever for 5 or more days with or without any of 
the principal clinical features of KD especially in the presence of 
supportive laboratory evidence such as elevated ESR, CRP, liver 
enzymes and bilirubin, low albumin, sterile pyuria and aseptic 
meningitis.(2)
CASE 3 – REFRACTORY KD
A 17-month-old boy was admitted to a local institution with an 
upper respiratory tract infection. He had a two day history of high 
fever, nasal congestion and cough. He was febrile, had evidence of 
non-exudative pharyngeal and tonsillar inflammation and non-
tender cervical lymphadenopathy. Initial treatment included anti-
pyretics, oral antibiotics, topical antiseptic and anti-inflammatory 
spray. Over the following 24 hours, he deteriorated rapidly devel-
oping persistent high fevers, a spreading erythematous poly-
morphous rash with hyperaemic swollen hands and feet and clinical 
meningism. His lumbar puncture was within normal limits. The 
CRP was raised at 53.6mg/l, his WCC was 25.8 x 109/l and he had 
a normochromic normocytic anaemia. Intravenous antibiotics were 
commenced and the diagnosis of Kawasaki disease entertained. 
Within a further 24 hours, he developed a hepatomegaly, bilateral 
conjunctivitis and cracked, red lips. At this point, he was given an 
IVIG infusion 2g/kg and commenced on high dose aspirin. His fever 
nevertheless continued to spike and his clinical condition worsened 
necessitating ICU admission. He developed a large hepatomegaly, 
rapid desquamation, severe conjunctivitis and abdominal distention 
associated with severe oedema. The dose of IVIG was repeated 
without any improvement. An echocardiogram revealed dilated 
left and right coronaries each measuring 2 - 3mm. He continued 
to deteriorate with rapidly increasing inflammatory markers (CRP 
334mg/l, ESR>150mm/hr). He was thus given a dose of methyl-
prednisolone of 10mg/kg over 4 hours. This resulted in significant 
hypertension of 160/120mmHg with the result that doses 2 and 3 
were administered over 6 hours. Although the blood pressure 
stabilised, the pyrexia continued and the patient remained 
extremely unwell, with progression of inflammatory activity evident. 
A repeat echocardiogram at this point showed further dilatation 
of both left main coronary and circumflex arteries up to 4 - 5mm 
FIGURE 5: Parasternal short axis view of proximal RCA 
saccular aneurysm in Case 2
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and progression in the dilatation of the right coronary now 
measuring 3mm. Finally on day 11, 9 days after admission and 6 
days after the first dose of IVIG, an infliximab infusion was given 
at 5mg/kg over several hours. By the following morning, the patient 
had improved dramatically, was afebrile for the first time since 
admission, able to eat, converse and play. His oedema rapidly 
resolved and within 72 hours, all his inflammatory markers had 
reduced and he was ready for discharge. A pre-discharge echo-
cardiogram revealed fusiform dilatation of left and right coronary 
arteries both measuring 3 - 4mm. No aneurysms were noted. 
Currently the patient is well and thriving.
DISCUSSION
The mainstay of treatment of KD remains intravenous immuno-
globulin (IVIG) in combination with high-dose aspirin followed by 
reduction in the aspirin dose following defervescence.(2) However, 
as the incidence of KD increases in the developed world so too 
do reports of immunoglobulin resistance.(10) Cases 1 and 3 above 
illustrate the problem of IVIG-resistant KD and raise the question 
of effective second-and third-line therapy.
Up to 15% of patients do not respond to an initial IVIG dose - these 
patients are at a significantly greater risk of developing CAA and 
may require re-treatment or further anti-inflammatory therapy.(11) 
The central culprit in KD is activation of the inflammatory cascade 
with an outpouring of cytokines producing both fever and the 
potentially devastating inflammatory vasculitis resulting in coronary 
and peripheral artery damage. A large US/Canadian study showed 
that patients who remained febrile had an almost nine-fold increase 
in CAA compared to those who responded to IVIG.(12) Thus it is 
critical to institute additional therapy in any child who remains 
febrile after treatment or re-treatment of KD with standard therapy. 
Corticosteroids have been suggested as a next step after a repeat 
dose of IVIG for more than a decade.(13)  However, this has been 
controversial with some reports suggesting that corticosteroids 
may in fact be harmful when used in this context.(14) A meta-analysis 
reviewing regimens including corticosteroids in the primary treat-
ment of Kawasaki disease revealed a significant reduction in re-
treatments with IVIG in patients receiving corticosteroid plus 
standard therapy compared to standard therapy alone.(15) There 
was however no significant reduction in the incidence of coronary 
artery aneurysms among patients who received corticosteroids plus 
standard therapy, compared to standard therapy alone. Recent data 
dispute these findings and suggest a significant beneficial effect 
of steroids.(16) It has also recently been reported as an adjunctive 
therapy for patients with severe KD in a large multi-centre, pro-
spective, randomised controlled trial (RAISE study).(7) This showed 
that in Japanese children, where prednisolone was added to the 
standard regimen of IVIG, the intensified primary treatment group 
had a significantly lower incidence of CAA.
Adjuvant and experimental therapies for refractory KD include 
additional doses of IVIG, methotrexate, abciximab, ulinastatin, 
cyclophosphamide, plasmapheresis and tumor necrosis factor-a 
(TNF-α) blockers such as infliximab.(17,18) Infliximab is a monoclonal 
antibody against TNF alpha and as such carries potential side-effects 
of immunosuppression or immune reactions. The rationale behind 
its use relates to suppressing the pro-inflammatory cytokines such 
as TNF-α, interleukins and endothelial growth factor that are 
elevated during the acute phase of KD. Increased serum levels of 
these correlate with coronary aneurysm and subsequent stricture 
formation. TNF-α blockade is now increasingly being used for KD 
patients with recrudescent fever or persistently elevated inflam-
matory markers to prevent the endothelial damage which is thought 
to result in severe endothelial cell dysfunction and apoptosis.(19) 
Clinical evidence to support the use of TNF-α blockade has been 
promising though anecdotal.(20,21) However in 2005, Burns, et al. 
reported a larger series of refractory KD patients treated using 
infliximab with excellent results.(22) More recently, these authors 
reported a randomised prospective trial that demonstrated the 
safety, tolerability and pharmacokinetics of TNF-α blockade versus 
a second dose of IVIG.(23) Importantly, studies of anti-TNF-α have 
not demonstrated increased side effects from drug administration 
such as infusion reactions, reactivation of infectious diseases (in par-
ticular tuberculosis), bacterial sepsis or increased risk of lymphoma. 
It is clear that further investigation of the role of infliximab in IVIG-
resistant patients is needed, especially as recognition of this con-
dition improves and more patients are diagnosed timeously.(24) 
Results are awaited from a recently completed large multi-centre 
study in the USA comparing standard therapy with standard therapy 
plus infliximab as initial therapy for all patients with KD.(25)
Patients not responding to these agents may be considered for 
other TNF-α blockade therapy. Etanercept (Enbrel) is another 
TNF-α inhibitor that has been studied in a few KD patients. Thus 
far it has shown some efficacy and is also under investigation as 
adjuvant therapy.(26) The calcineurin inhibitor, cyclosporine A (CSA) 
has long been used as a potent immunosuppressive in transplanta-
tion. A new role has been suggested for CSA in refractory KD. This 
follows evidence of the role that T cells and calcineurin/nuclear 
factor of the activated T cell NFAT pathway play in KD.  As CSA 
is a potent inhibitor of T cells via inhibition of the same NFAT 
pathway, this strategy seems opportune. A recent publication has 
detailed a protocol using CSA in IVIG -resistant KD.(27,28) Other 
therapies for refractory KD have been limited to case series and 
reports and include successes with methotrexate, plasma exchange 
and ulinastatin, a trypsin inhibitor. However, these therapies, though 
promising, need further study.(29)


















In summary, repeat IVIG remains the initial second-line therapy for 
continued fever followed by corticosteroids. In cases refractory to 
both these therapies, infliximab is the most commonly used third-
line agent.
Figure 6 summarises the current recommendations for initial 
therapy and outlines options for second and third-line treatment. 
As more KD patients are encountered, the importance of con-
sidering these treatment options must be stressed if 2 doses of
IVIG do not result in the desired defervescence and reduction in 
inflammatory markers.
CONCLUSION
Kawasaki disease is responsible for significant cardiovascular mor-
bidity with often permanent sequelae and potential major impact 
on cardiovascular health in later life. This can be minimised with 
improved recognition of the condition together with awareness of 
incomplete presentations amongst general practitioners and paedi-
atricians followed by prompt and appropriate therapy to reduce 
the incidence of potentially devastating CAA. Further improvements 
in outcomes may come from early recognition of children at 
greatest risk for IVIG-resistance and development of CAA in order 
to provide adjunctive corticosteroids to the primary treatment 
(which are relatively cheap and therefore promise to be the most 
effective approach in developing countries) as well as other poten-
tial primary therapies such as TNF-α blockade to prevent the 
development of coronary complications.
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FIGURE 6:  Treatment algorithm for refractory Kawasaki Disease
■  Standard regimen.
■  IVIG 2g/kg + high dose acetylsalicylic acid (ASA) 80 - 100mg/kg/d in 4 doses.
■  Current research: Adjuvant therapy with corticosteriods in high-risk patients appear advantageous.
■  TNF-α Blockade such as Infliximab IV 5mg/kg + high dose ASA.
■   Current research: Infliximab shown to be safe and efficacious. Adjuvant infliximab to initial therapy under 
observation.
■  If no response after 36 hours: Repeat IVIG 2g/kg + maintain high dose ASA.
■  If still no response after a further 36 hours: Introduce methylprednisolone IV 30mg/kg/d in 1 - 3 pulsed doses.
■   Current research: Beta-Blockade ± Heparin indicated in severe coronary lesions. Increased therapy required if no 
defervescence or escalating inflammatory markers.
■  TNF-α Inhibitors such as Etanercept + high dose ASA.




■   Current research: Promising case reports and case series, however large studies demonstrating efficacy and 
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